Immunohistochemistry, as the gold standard to analyze the expression of target proteins, is unable to capture the dynamic changes of PD-L1 expression during tumor progression or to provide an overview picture of PD-L1 expression in heterogenic tumors [6]. Here, CD274 is linked to neoplasm.